ADVERTISEMENT

High-risk breast cancer: metformin fails phase 3 randomized, placebo-controlled, double-blind trial

Miriam Davis, PhD   |   Clinical Summary   |   23 June 2022
ADVERTISEMENT

Takeaway

  • Oral metformin given for 5 years to nondiabetic patients with high-risk stage I-III breast cancer fails to extend invasive disease-free survival (DFS), according to a phase 3 randomized clinical trial (RCT) known as MA.32.

Why this matters

  • Metformin had shown promise in observational and preclinical studies.

Study design

  • Phase 3...

          

January Challenge

Ends in 2d 15h
left
right

Topic Challenges

left
right